<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K799DP4&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe>
NAS:GLPG (Belgium) Also Trade In: Austria Belgium Germany Netherlands UK

Galapagos NV $ 157.52 0 (0%)

Volume:
97,652
Avg Vol (1m):
126,916
Market Cap $:
9.76 Bil
Enterprise Value $:
8.52 Bil
P/E (TTM):
0.00
P/B:
6.78
Warning! GuruFocus has detected 1 Severe warning sign with GLPG. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)

GLPG News and Headlines - Galapagos NV

GuruFocus Articles Total 57
  • 1
  • 2
  • 3

The nearly $83 billion biotech giant seems poised to supercharge its M&A and partnership efforts

With Andrew Dickinson assuming the additional role of chief financial officer at Gilead Sciences (GILD), the company appears poised to take center stage on “Let’s Make a Deal.”

A large number of analysts think that adding the role of financial chief to Dickinson’s portfolio signals the big biotech is going to be aggressively pursuing mergers, acquisitions and partnerships, according to an Oct. 15 article in FiercePharma.

Dickinson, who will retain responsibility for business development, masterminded Gilead’s nearly $12 billion purchase of Kite Pharma in 2017, a deal that got the company into cancer and cell therapy. In July, Gilead laid

110 Views    Barry Cohen    2019-10-18 14:22
For the first time since FierceBiotech issued its list, companies outside the US are included

In a Sept. 23 article, GuruFocus highlighted three of the 15 private and independent biotechs recognized by a key industry publication for their innovation. As suggested in the piece, investors may want to keep an eye on these firms, many of which could eventually go public. They could also come under the wing of an established member of pharma, bringing the acquirer a novel platform or helping it move into growing areas of therapy. Both could substantially boost the valuation of the parent.

For the first time in 2019, FierceBiotech considered foreign firms for recognition. One that made

108 Views    Barry Cohen    2019-09-26 15:38

  • First half-year financial results:
    • Group revenues of €108.5 million
    • Operating loss of €97.6 million
    • Net loss of €95.9 million
    • Cash and cash equivalents on 30 June 2019 of €1,148 million
  • Further development of our broad and deep pipeline:
    • Reported positive data with filgotinib in FINCH 1 and 3 Phase 3 trials in rheumatoid arthritis
    • Completed recruitment of ROCCELLA Phase 2b trial with GLPG1972 in osteoarthritis, with Servier
    • Initiated GECKO Phase 2 trial in atopic
0 Views    Marketwired    2019-07-26 00:00

Mechelen, Belgium; 18 July 2019; 22.01 CET; regulated information - Galapagos NV (Euronext & GLPG) received a transparency notification from Van Herk Investments B.V.

Pursuant to Belgian transparency legislation[1], Galapagos received a transparency notification on 16 July 2019 from Van Herk Investments B.V., who notified that it holds 5,792,737 of Galapagos' voting rights, consisting of ordinary shares (4,899,498) and American Depository Receipts (893,239). This represents 10.57% of Galapagos' currently outstanding 54,823,101 shares. Van Herk Investments B.V. thus crossed above the 10% threshold of Galapagos' voting

0 Views    Marketwired    2019-07-19 00:00
Galapagos skyrockets to an all-time high

U.S. stocks were mixed on Monday as banks and tech companies kick off second-quarter earnings. The Dow Jones Industrial Average gained 0.02% to 27,336, the S&P 500 Index slid 0.06% to 3,012 and the Nasdaq Composite Index swelled 0.14% to 8,255.

Shares of Galapagos NV (GLPG) gained more than 17% on news that Gilead Sciences (GILD) will inject funds up to $5.1 billion to gain rights to six drugs in clinical trials and also gain access to earlier-stage programs. The deal is to be funded by $3.95 billion in

265 Views    Omar Venerio    2019-07-15 20:34

- Gilead to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment -

- Gilead Gains Access to Galapagos' Differentiated Drug Discovery Platform and Current and Future Pipeline Outside of Europe -

- Investment Enables Galapagos to Expand and Accelerate Research and Clinical Programs -

- Galapagos Gains Broader Commercialization Role for Filgotinib in Europe and Agrees to Share Equally in Future Development Costs -

- Gilead Agrees to 10-year Standstill -

Foster City, Calif. and Mechelen, Belgium -- July 14,

0 Views    Marketwired    2019-07-14 20:00

Mechelen, Belgium; 2 July 2019; 07.00 CET; regulated information - Gilead Sciences, Inc. ( GILD) today announced that at a recent pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA), the company provided an update about the investigational oral, selective JAK1 inhibitor, filgotinib. The company discussed with the agency the Phase 3 FINCH studies, as well as the ongoing Phase 2 MANTA safety study assessing semen parameters with filgotinib treatment in men with moderately to severely active ulcerative colitis or Crohn's disease. As

0 Views    Marketwired    2019-07-02 08:00

Mechelen, Belgium; 20 June 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & GLPG) announces a share capital increase arising from warrant exercises.

Galapagos issued 208,310 new ordinary shares on 20 June 2019, for a total capital increase (including issuance premium) of €4,325,094.48.

Pursuant to the warrant exercise program of Galapagos' executive committee, executive committee members automatically are committed to exercise a minimum number of warrants, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe

0 Views    Marketwired    2019-06-21 00:00

Mechelen, Belgium; 17 June 2019; 22.01 CET; regulated information - Galapagos NV (Euronext & GLPG) received a transparency notification from The Capital Group Companies, Inc.

Pursuant to Belgian transparency legislation[1], Galapagos received a transparency notification on 6 June 2019 from The Capital Group Companies, Inc. who notified that it controls Capital Research and Management Company, which holds 2,772,024 of Galapagos' voting rights, consisting of ordinary shares. This represents 5.08% of Galapagos' currently outstanding 54,614,791 shares. The Capital Group Companies, Inc. thus crossed above the 5%

0 Views    Marketwired    2019-06-18 00:00

Mechelen, Belgium and Paris, France, 11 JUNE 2019, 07.00 CET - Servier and Galapagos NV (Euronext & GLPG) completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule.

ROCCELLA is a multi-regional, randomized, double-blind, placebo-controlled, dose ranging trial evaluating the efficacy and safety of three different once-daily oral doses of GLPG1972/S201086 in patients with knee osteoarthritis (OA).  ROCCELLA includes more than 850 patients in 12 countries in Europe, Asia, North and South America. Galapagos is responsible for ROCCELLA in the United States,

0 Views    Marketwired    2019-06-11 08:00

-- Phase 3 FINCH 1 and FINCH 3 Data of Filgotinib in Rheumatoid Arthritis to Be Featured in Opening Plenary and Late Breaker Sessions --

Foster City, Calif. and Mechelen, Belgium; May 29, 2019; 22.30 CET - Gilead Sciences, Inc. ( GILD) and Galapagos NV (Euronext & GLPG) today announced that data on filgotinib, an investigational, oral, selective JAK1 inhibitor, will be presented at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain, on June 12-15, 2019. Among the abstracts to be presented

0 Views    Marketwired    2019-05-30 00:00
Health care-oriented fund’s top buys include one new holding and four position boosts

The Vanguard Health Care Fund (Trades, Portfolio) disclosed this week its top five buys for the first quarter included a new position in Galapagos NV (GLPG) and position boosts of the following four companies: Elanco Animal Health Inc. (ELAN), Teva Pharmaceuticals Industries Ltd. (TEVA), Centene Corp. (CNC) and Eisai Co. Ltd. (TSE:4523).

Managed by Jean Hynes, the fund seeks long-term capital appreciation through investments in domestic and foreign companies in various industries within the health care sector. As of quarter-end, the 89-stock equity portfolio contains 97.65% exposure to health care, with a buy impact of 3.25% and

371 Views    James Li    2019-05-02 16:51

Key Q1 2019 results:

  • Group revenues of €40.9 million
  • Operating loss €53.2 million
  • Net loss of €48.7 million
  • End of first quarter cash and cash equivalents €1.2 billion
  • Competitive safety and efficacy results with filgotinib in FINCH 1 and 3 Phase 3 trials in RA
  • Clinical progress reported in broad and growing inflammation and fibrosis pipeline

 

Webcast presentation tomorrow, 26 April 2019, at 14.00 CET/8 AM ET,

+32 2 404 0659, code 1452466, www.glpg.com

 

0 Views    Marketwired    2019-04-26 00:00

Mechelen, Belgium and Planegg/Munich, Germany; 23 April 2019; 22:01 CET; Galapagos NV (Euronext & GLPG), MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; MOR) and Novartis Pharma AG (SIX: NOVN-CH) announced today the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.

The GECKO trial aims to randomize 60 patients who receive either a dose of MOR106 or placebo subcutaneously for 8 weeks, together with topical steroids, with

0 Views    Marketwired    2019-04-24 00:01

Mechelen, Belgium; 10 April 2019, 22.01 CET; regulated information -- Galapagos NV (Euronext & GLPG) announced today that its board of directors created 2,070,000 warrants under new warrant plans for the benefit of the employees, directors, and a consultant of the company and its subsidiaries.

On 10 April 2019, the board of directors of Galapagos approved "Warrant Plan 2019 RMV," intended for the employees of its French subsidiary, Galapagos SASU, and "Warrant Plan 2019", intended mainly for the employees of the company and its subsidiaries, and for directors

0 Views    Marketwired    2019-04-11 00:00

NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cisco Systems, Inc. (CSCO), NanoString Technologies, Inc. (NSTG), Galapagos NV (GLPG), A10 Networks, Inc. (:ATEN), International Seaways Inc. (:INSW), and Scholastic Corporation (SCHL), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CSCO

0 Views    Marketwired    2019-04-04 12:01

-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile --

 

Foster City, Calif. and Mechelen, Belgium; March 28, 2019, 22.03 CET; regulated information - Gilead Sciences, Inc. ( GILD) and Galapagos NV (Euronext & GLPG) today also announced interim safety information from four studies of the investigational compound filgotinib for the treatment of rheumatoid arthritis (RA). The data include 24 week results of the ongoing Phase 3 FINCH 1,

0 Views    Marketwired    2019-03-29 00:02

-- Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone --

-- Filgotinib Safety Profile Consistent With Previously Reported Results --

 

Foster City, Calif. and Mechelen, Belgium; March 28, 2019; 22.01 CET; regulated information - Gilead Sciences, Inc. ( GILD) and Galapagos NV (Euronext & GLPG) today announced Week 24 results of FINCH 3, an ongoing, randomized, double-blind, active-controlled Phase 3 study of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid

0 Views    Marketwired    2019-03-29 00:01

  
-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile --

Foster City, Calif. and Mechelen, Belgium; March 28, 2019, 22.03 CET; regulated information - Gilead Sciences, Inc. ( GILD) and Galapagos NV (Euronext & GLPG) today also announced interim safety information from four studies of the investigational compound filgotinib for the treatment of rheumatoid arthritis (RA). The data include 24 week results of the ongoing Phase 3 FINCH 1, 2, and 3

0 Views    Marketwired    2019-03-29 00:01

                                       
-- Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior Inadequate Methotrexate Response --

-- Significant Inhibition of Radiographic Progression Demonstrated with Both Doses of Filgotinib versus Placebo --

-- Safety Profile of Filgotinib Consistent with Previously Reported Results --

Foster City, Calif. and Mechelen, Belgium; March 28, 2019; 22.00 CET; regulated information - Gilead Sciences, Inc. ( GILD) and Galapagos NV (Euronext & GLPG) today announced Week 24 results of FINCH 1, an ongoing, randomized, double-blind,

0 Views    Marketwired    2019-03-29 00:00

Headlines Total 199
  • 1
  • 2

2019-10-18 $ 157.02 (-3.67%)
10:17am
2019-10-11 $ 155.46 (-1.29%)
8:19am
2019-10-09 $ 155.23 (2.5%)
10:10am
2019-10-07 $ 150.13 (-1.03%)
5:32pm
2019-10-04 $ 151.7 (0.74%)
10:48am
2019-09-22
2:00pm
2019-09-03 $ 166.96 (-0.72%)
4:46pm
2019-08-29 $ 168.7 (0.06%)
8:00am
2019-08-28 $ 168.6 (-0.79%)
9:34am
2019-08-26 $ 165.18 (1.36%)
8:42am
7:28am
2019-08-16 $ 172.18 (1.54%)
8:19am
2019-08-05 $ 170.54 (-1.13%)
1:08pm
2019-07-31 $ 173.4 (-1.95%)
8:55am
2019-07-26 $ 180.25 (0.68%)
10:50am
9:11am
2019-07-25 $ 179.03 (0.31%)
7:00pm
2019-07-22 $ 187.64 (2.31%)
9:37am
9:37am
2019-07-18 $ 174.01 (2.43%)
7:00pm
2019-07-17 $ 169.88 (-1.12%)
1:16pm
9:06am
7:15am
2019-07-16 $ 171.8 (0.61%)
7:40pm
8:50am
7:27am
2019-07-15 $ 170.76 (17.16%)
4:50pm
3:29pm
9:21am
7:59am
7:38am
2019-07-14
3:00pm
2019-07-09 $ 136.93 (0.94%)
12:52pm
2019-07-02 $ 135.77 (4.09%)
8:54am
3:00am
2019-06-20 $ 127.97 (1.48%)
7:00pm
2019-06-17 $ 121 (-0.15%)
7:00pm
2019-06-12 $ 123.36 (0.5%)
5:38pm
2019-06-11 $ 122.75 (1.05%)
3:00am
2019-06-05 $ 116.36 (0.14%)
12:46pm
2019-05-29 $ 114.9 (-1.73%)
7:00pm
2019-05-28 $ 116.92 (-2.03%)
3:02pm
2019-05-19
2:00pm
2019-05-12
9:01am
2019-05-02 $ 113.47 (0.07%)
11:51am
2019-04-28
11:33pm
2019-04-26 $ 112.09 (-0.68%)
9:46pm
2019-04-25 $ 112.86 (0.56%)
7:00pm
2019-04-23 $ 115 (0.6%)
7:01pm
2019-04-10 $ 121.87 (-1.28%)
7:00pm
2019-04-09 $ 123.45 (-0.55%)
7:46am
2019-04-08 $ 124.13 (-0.45%)
4:25pm
2019-04-01 $ 116.68 (-0.93%)
9:15am
2019-03-29 $ 117.78 (22.52%)
4:32pm
11:31am
11:06am
8:13am
2019-03-28 $ 96.13 (0.53%)
7:02pm
7:01pm
7:01pm
7:00pm
2019-03-20 $ 103.24 (2.16%)
7:00pm
2019-03-09
6:00am
2019-03-07 $ 97.27 (-2.07%)
6:03am
2019-02-22 $ 98.18 (0.34%)
3:12pm
11:07am
2019-02-21 $ 97.85 (-3.16%)
7:04pm
2019-02-07 $ 101.3 (1.64%)
3:00am
2019-01-08 $ 103.43 (2.8%)
7:01pm
2019-01-07 $ 100.61 (3.25%)
3:01am
2019-01-06
7:01pm
2019-01-04 $ 97.44 (8.74%)
7:00pm
2018-12-27 $ 88.21 (-4.2%)
7:25am
2018-12-21 $ 91.59 (-3.18%)
7:00pm
2018-12-17 $ 101.78 (-2.25%)
7:01pm
2018-11-28 $ 100.75 (2.92%)
4:19pm
2018-11-27 $ 97.89 (-2.78%)
7:02pm
2018-11-26 $ 100.69 (0.35%)
7:02pm
2018-11-23 $ 100.34 (1.24%)
7:00pm
2018-11-19 $ 101.35 (-3.14%)
2:51pm
2018-11-12 $ 101.85 (-3.91%)
9:08am
8:04am
2018-10-31 $ 102.73 (3.19%)
7:01pm
2018-10-29 $ 99.62 (2.43%)
3:51pm
2018-10-27
9:10am
2018-10-24 $ 100.36 (-4.29%)
7:04pm
2018-10-22 $ 107.9 (0.16%)
4:36pm
2018-09-29
8:00am
$GLPG Galapagos Valuation - seekingalpha.com
2018-09-21 $ 113.31 (-1.69%)
8:33am
$GLPG $GILD Next Gilead - seekingalpha.com
2018-09-17 $ 115.62 (-1.6%)
8:35am
2018-09-13 $ 120.22 (0.43%)
1:22pm
10:18am
2018-09-12 $ 119.71 (16.52%)
2:40pm
2018-09-11 $ 102.74 (5.52%)
7:01pm
2018-09-10 $ 97.37 (2.12%)
10:35am
2018-09-07 $ 95.35 (2.42%)
9:45am
2018-09-06 $ 93.1 (-4.02%)
2:25pm
2018-09-04 $ 98.66 (-2.66%)
8:40am
2018-08-08 $ 111.84 (-0.15%)
9:49am
2018-08-07 $ 112.01 (2.69%)
9:52am
Total 199
  • 1
  • 2